Berberine Protects Against Palmitate-Induced Apoptosis in Tubular Epithelial Cells by Promoting Fatty Acid Oxidation

Background: Increased lipid accumulation in renal tubular epithelial cells (TECs) contributes to their injury and dysfunction and progression of tubulointerstitial fibrosis. Berberine (BBR), a natural plant alkaloid isolated from traditional medicine herbs, is effective in lowering serum lipid, and has a protective effect on chronic kidney disease (CKD) with dyslipidemia, including diabetic nephropathy. The aim of this study was to investigate the effect of BBR on palmitate (PA)-induced lipid accumulation and apoptosis in TECs.

Material/Methods: Human kidney proximal tubular epithelial cell line (HK-2) cells were treated with PA, BBR, and/or palmitoyltransferase 1A (CPT1A) inhibitor Etoromoxir. Intracellular lipid content was assessed by Oil Red O and Nile Red staining. Cell apoptosis rate was evaluated by flow cytometry assay. The expression of apoptosis-related protein cleaved-caspase3 and fatty acid oxidation (FAO)-regulating proteins, including CPT1A, peroxisome proliferator-activated receptor α (PPARα), and PPARγ co-activator-1α (PGC1α), was measured by Western blot analysis and immunofluorescence.

Results: In the present study, PA treatment increased intracellular lipid deposition accompanied by elevated apoptosis in TECs compared with control group, whereas the protein expression of CPT1A, PPARα, and PGC1α, did not correspondingly increase in TECs. BBR significantly up-regulated the protein expression of CPT1A, PPARα, and PGC1α in TECs treated with or without PA, and reversed PA-induced intracellular lipid accumulation and apoptosis. Moreover, the CPT1A inhibitor Etoromoxir counteracted the protective effect of BBR in TECs.

Conclusions: These in vitro findings suggest that PA can induce intracellular lipid accumulation and apoptosis in TECs, and the mechanism may be associated with inducing defective FAO, whereas BBR can protect TECs against PA-induced intracellular lipid accumulation and apoptosis by promoting FAO.

MeSH Keywords: Apoptosis • Berberine • Fatty Acid Oxidation • Palmitic Acid • Tubular Epithelial Cells

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/908927
Background

Chronic kidney disease (CKD) is usually accompanied by lipid abnormalities [1–3]. Since the “lipid nephrotoxicity hypothesis” was first proposed by Moorhead in 1982 [4], increasing evidence has supported the hypothesis that filtered non-esterified fatty acid or lipoprotein causes renal epithelial cell injury and promotes the progression of renal disease [5].

Intracellular lipid accumulation has been found in human and mouse kidneys with tubulointerstitial fibrosis [6]. Moreover, lipid accumulation in the kidney leads to structural impairment of tubular epithelial cells (TECs) and associated inflammation and fibrosis in high-fat diet (HFD)-fed mice [7]. These findings demonstrate that lipid accumulation in TECs plays a critical role in tubulointerstitial fibrosis. TECs depend primarily on fatty acid oxidation (FAO) as their energy source. Intracellular lipid accumulation is associated with an imbalance between uptake and oxidation of fatty acids [8]. Moreover, it has been shown that improving FAO protects mice from tubulointerstitial fibrosis [6]. These findings suggest that defective FAO can lead to lipid accumulation in TECs and thus contribute to TEC injury and tubulointerstitial fibrosis.

Berberine (BBR), a natural plant alkaloid originally extracted from Coptis chinensis (“Huanglian” in Chinese), has been commonly used to treat diarrhea for at least a century in China, and its safety has been confirmed [9–11]. In recent years, it has been found that BBR is effective in lowering serum lipid (including serum cholesterol, triglyceride, and LDL-cholesterol), has a significant effect on the treatment of CKD with dyslipidemia (including diabetic nephropathy), and has been widely used in clinical therapy [12,13]. However, the mechanism responsible for the renal-protective effect of BBR has not been completely understood. Some researchers reported that the renal-protective effect of BBR may be associated with anti-oxidative stress and inhibiting aldose reductase in diabetic nephropathy [14]. Recently, to further explore how BBR protects against cell and organ injury caused by dyslipidemia, studies on the effect of BBR on intracellular lipid were performed. It has been shown that BBR can reduce lipid accumulation and promote FAO in liver in db/db mice [15], and can ameliorate PA-induced apoptosis in pancreatic β cells in vitro [16]. However, the specific mechanism has not been well defined, and it remains unclear whether BBR has a similar effect in TECs. In the present study we investigated the effect of BBR on PA-induced lipid accumulation and apoptosis in TECs using an in vitro model and sought to determine the underlying mechanism.

Material and Methods

Cell culture

Human kidney proximal tubular epithelial cell line (HK-2) cells were obtained from the American Type Culture Collection (Manassas, VA, USA). HK-2 cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin in a humidified 5% CO2 incubator at 37°C. For treatment of HK-2 cells, sodium palmitate (Sigma, USA, P9767) was prepared as a 2.5 mmol/L stock solution, as described previously [17]. For treatment of HK-2 cells, BBR (Sigma, USA) was prepared as a 25 mmol/L stock solution by dissolving it in DMSO, and Etomoxir (Selleck, USA) was prepared as a 50 mmol/L stock solution by dissolving it in DMSO. Cells were treated with sodium palmitate after pretreatment with BBR and/or Etomoxir, and then intracellular lipid accumulation, FAO-related protein expression, and cell apoptosis were assessed.

Flow cytometric assay

Apoptosis was detected using the Annexin V-FITC/propidium iodide (PI) apoptosis assay kit (Sungeen Biotech, China). Briefly, treated cells were collected by centrifugation, washed twice with ice-cold PBS, and then resuspended in 500 μl of 1× Annexin V binding buffer containing 5 μl of Annexin V-FITC and 3 μl of PI. After incubation for 10 min at room temperature, the percentage of apoptotic cells was analyzed using a flow cytometer (BD FACSCalibur, Becton-Dickinson, USA). The apoptosis rate of HK-2 cells was calculated as early apoptotic (annexin V+/PI−) rate plus late apoptotic (annexin V+/PI+) rate.

Western blot analysis

Cells were lysed in RIPA lysis buffer (Beyotime, China), sonicated for 15 s, and then centrifuged at 12 000 g for 15 min at 4°C. Then, the protein samples were mixed with loading buffer, heated at 100°C for 5 min, separated by electrophoresis in 10% or 12% tris-glycine polyacrylamide gradient gels, transferred onto PVDF membrane (Millipore, USA), blocked with 5% non-fat milk for 1 h at room temperature, and then incubated overnight at 4°C with different primary antibodies: mouse anti-carnitine palmitoyltransferase 1A (CPT1A, 1: 1000, Novus, USA), or mouse anti-peroxisome proliferator-activated receptor α (PPARα, 1: 500, Santa Cruz, USA), rabbit anti-PPARy co-activator-1α (PGC1α, 1: 1000, Novus, USA), or mouse anti-β-actin (1: 5000, Sungene Biotech, China). After washing with TBS-T, the membrane was incubated with goat anti-mouse IgG(H+L) horse- radish peroxidase (1: 8000, MultiSciences, China) or goat anti-rabbit IgG(H+L) horse-radish peroxidase (1: 8000, MultiSciences, China) for 1 h and then incubated with ECL reagent (Advansta, USA). Protein expression and its safety has been confirmed [9–11]. In recent years, it has been commonly used to treat diarrhea for at least a century in China, and its safety has been confirmed [9–11]. In recent years, it has been found that BBR is effective in lowering serum lipid (including serum cholesterol, triglyceride, and LDL-cholesterol), has a significant effect on the treatment of CKD with dyslipidemia (including diabetic nephropathy), and has been widely used in clinical therapy [12,13]. However, the mechanism responsible for the renal-protective effect of BBR has not been completely understood. Some researchers reported that the renal-protective effect of BBR may be associated with anti-oxidative stress and inhibiting aldose reductase in diabetic nephropathy [14]. Recently, to further explore how BBR protects against cell and organ injury caused by dyslipidemia, studies on the effect of BBR on intracellular lipid were performed. It has been shown that BBR can reduce lipid accumulation and promote FAO in liver in db/db mice [15], and can ameliorate PA-induced apoptosis in pancreatic β cells in vitro [16]. However, the specific mechanism has not been well defined, and it remains unclear whether BBR has a similar effect in TECs. In the present study we investigated the effect of BBR on PA-induced lipid accumulation and apoptosis in TECs using an in vitro model and sought to determine the underlying mechanism.
Blot images were captured by an imaging densitometer (Fusion FX5, Vilber Lourmat, France), band densitometry was scanned by the Fusion analysis software, and targeted protein expression levels were quantitated relative to β-actin and expressed as fold change (normalized to control group).

**Immunofluorescence**

Cells were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.1% Triton X-100 for 10 min, blocked with 5% BSA (Sigma, USA) for 1 h at room temperature, incubated overnight at 4°C with mouse anti-CPT1A antibody (1: 400, Abcam, UK), washed with PBS 3 times, and then incubated with green-fluorescent Alexa Fluor 488 goat anti-mouse IgG antibody (1: 400, Invitrogen, USA) for 1 h. After washing with PBS 3 times, cells were stained with 4, 6-diamidino-2-phenylindole (DAPI; Invitrogen, USA) for 3 min and visualized with a fluorescence microscope (DM4000 B LED, Leica, Germany) at wavelengths of 488 nm for excitation and 525 nm for emission.

**Measurement of intracellular lipid content**

Intracellular lipid content was measured with Oil Red O and Nile Red staining. Cells were first fixed with 4% paraformaldehyde for 30 min. For Oil Red O staining, cells were stained with Oil Red O (0.18g/ml, Sigma, USA) for 15 min at 37°C, and then counterstained with hematoxylin for 3 min. For Nile Red staining, cells were incubated with Nile Red (0.1 ug/ml, Sigma, USA) for 10 min, and then stained with DAPI for 3 min. Then, cells were visualized under a microscope (DM4000 B LED, Leica, Germany). All fluorescence intensity was quantified using Image J software.

**Statistical analysis**

Data are presented as mean ±SEM from 3 independent experiments. Analyses were carried out using GraphPad Prism Software version 7.00 (San Diego, CA). Differences among different groups were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for analysis of differences between groups. The level of statistical significance was defined as p<0.05.

**Results**

**BBR ameliorated PA-induced apoptosis in TECs**

HK-2 cells were treated with different concentration of PA for 24 h, and cleaved-caspase3 protein expression was measured by Western blotting. There was a significant increase in cleaved-caspase3 protein expression in the 300 μmol/L PA group and 450 μmol/L PA group compared with the control group (Figure 1A, 1B). Moreover, cleaved-caspase3 protein expression in the 450 μmol/L PA group was dramatically higher than that in the 300 μmol/L PA group (Figure 1A, 1D). Thus, we chose PA at a concentration of 450 μmol/L to treat HK-2 cells in the following experiments. Using annexin V-FITC/PI staining and flow cytometric analysis, we also confirmed that the exposure of HK-2 cells to 450 μmol/L PA induced obvious apoptosis in TECs (Figure 1E, 1F). In addition, HK-2 cells were incubated with 450 μmol/L PA in the presence or absence of 12.5 μmol/L BBR for 24 h, and BBR treatment ameliorated PA-induced apoptosis (Figure 1C–1F).

**BBR decreased PA-induced lipid accumulation in TECs**

Intracellular lipid content was detected with the use of Oil Red O and Nile Red staining. PA induced a significant increase of lipid content in HK-2 cells, whereas BBR significantly reduced PA-induced intracellular lipid accumulation (Figure 2A–2C). Oil Red O can stain neutral triglycerides, and Nile Red can stain various of neutral lipids including neutral triglycerides and cholesterol esters. Therefore, increased intracellular lipid induced by PA contained neutral triglycerides.

**BBR promoted FAO of TECs**

To investigate how BBR decreases PA-induced lipid accumulation in TECs, we assessed the expression of FAO-related proteins, including CPT1A, PPARα, and PGC1α, by Western blotting. After treatment with 2.5 μmol/L or 12.5 μmol/L BBR, the expression of each of these 3 proteins was significantly up-regulated compared with the control group, whereas 12.5 μmol/L BBR caused a higher level than that of 2.5 μmol/L BBR (Figure 3A, 3B). We chose BBR at a concentration of 12.5 μmol/L to treat HK-2 cells in the following experiment. Our results showed that BBR promoted the protein expression of CPT1A, PPARα, and PGC1α in the presence or absence of PA treatment (Figure 3C, 3D). Using immunofluorescence staining, we also found that BBR increased the protein expression of CPT1A, the key enzyme in the regulation of FAO, in the presence or absence of PA treatment (Figure 3E, 3F). Taken together, these results suggest that BBR promotes FAO in TECs treated with or without PA. However, there was no statistically significant difference in the protein expression of CPT1A, PPARα, or PGC1α between the PA group and control group (Figure 3C–3F).

**CPT1A inhibitor counteracted the protective effect of BBR against PA-induced lipid accumulation and apoptosis in TECs.**

To determine whether the protective effect of BBR against PA-induced lipid accumulation and apoptosis is associated with elevating FAO, HK-2 cells were treated with 40 μmol/L CPT1A...
inhibitor Etomoxir for 48 h. Results showed that Etomoxir induced significantly increased intracellular lipid-droplet formation, accompanied by increased cleaved-caspase3 protein expression and apoptosis in HK-2 cells treated with PA and BBR (Figure 4A–4G), suggesting that inhibition of FAO counteracted the protective effect of BBR.

**Discussion**

Clinical and experimental evidence indicates that dyslipidemia contributes to CKD progression by inducing inflammatory, oxidative stress, and endoplasmic reticulum stress, and lipid-lowering agents might protect renal function [18]. Excess lipid, especially triglycerides, beyond that needed for cellular structures...
and ATP generation is stored as lipid droplets in adipocytes. However, too great of an excess will overburden these cells and cause ectopic deposition of lipids in non-adipose cells such as proximal tubular cells. Lipid droplets are often seen in proximal tubular cells in nephrotic syndrome [19]. When the lipid-storage capacity of non-adipose cells is exceeded, triglycerides are hydrolyzed to produce excess free fatty acids (FFAs), which can increase reactive oxygen species production and endoplasmic reticulum stress, leading to cell dysfunction and injury, collectively termed lipotoxicity [5,20]. Apoptosis is one of major types of cell death, a key and active process to keep tissue homeostasis and to clear potentially harmful cells away in multicellular organisms [21], and inappropriate (either too much or too little) apoptosis is widely involved in the pathophysiology of human diseases [22]. Kinetic experiments using mouse models of focal and segmental glomerulosclerosis showed that apoptosis of TECs is the main cause of tubular atrophy, which has been confirmed as an important predictor of CKD progression [23]. In the present study, we demonstrated that PA treatment increased intracellular lipid deposition, including triglycerides deposition, accompanied by elevated apoptosis in TECs, indicating that excessive intracellular lipid leads to lipotoxicity and therefore induces TECs apoptosis.

Figure 2. Berberine decreased palmitate-induced lipid accumulation in HK-2 cells. Intracellular lipid content was detected by Oil Red O staining (400×) (A) and Nile Red staining (400×) (B). The lower panels show enlarged views of the boxed areas in the upper panels in Figure A. The lowest panels show enlarged views of the boxed areas in the upper panels in Figure B. (C) Fluorescent intensity from 5 randomly selected microscopic fields per group in Figure b was captured and analyzed. The statistical data are expressed as the mean ±SEM; n=3. * p<0.05 vs. control group. * p<0.05 vs. PA group.
Intracellular lipid accumulation is attributed to the imbalance between uptake and oxidation of fatty acids [8]. FAO requires fatty acids to translocate into mitochondria, which is a rate-limited step regulated by CPT1 in the oxidation of long-chain fatty acids [24]. CPT1A, the primary isoform expressed in the kidneys [25], is responsible for transporting acyl CoA into mitochondria [26]. PPARα promotes the protein expression of CPT1A with the cooperation of PGC1α [27], and consequently increases FAO [28]. Recently, it was proposed that the cooperation of PPARα and PGC1α plays a critical role in matching FAO capacity to substrate availability [29]. Therefore, in general, if FFA supply increases, the expression of PPARα and PGC1α will correspondingly increase and thus up-regulate CPT1A expression. Otherwise, the imbalance between high FFA level and relatively low FAO level will induce excessive intracellular lipid accumulation and then cause lipotoxicity, leading to cell

Figure 3. Berberine promoted fatty acid oxidation in HK-2 cells. (A) Representative Western blot analyses of CPT1A, PPARα, and PGC1α protein expression. (B) Densitometric analysis of CPT1A, PPARα, and PGC1α expression in Figure A. (C) Representative Western blot analyses of CPT1A, PPARα, and PGC1α protein expression. (D) Densitometric analysis of CPT1A, PPARα, and PGC1α protein expression in Figure C. (E) Representative immunofluorescence images of CPT1A protein expression (400×). The lowest panels showed enlarged views of the boxed areas in the upper panels. (F) Fluorescence intensities from 5 randomly selected microscopic fields per group in Figure e were measured and analyzed. All the statistical data are presented as the mean ±SEM from 3 independent experiments. * p<0.05 vs. control group. # p<0.05 vs. PA group.
Figure 4. CPT1A inhibitor counteracted the protective effect of BBR against PA-induced lipid accumulation and apoptosis in HK-2 cells. HK-2 cells were pretreated with or without 40 μmol/L Etomoxir for 24 h, and then treated with 12.5 μmol/L BBR in the presence or absence of 450 μmol/L PA for 24 h. Intracellular lipid content was detected by Oil Red O staining (400×) (A) and Nile Red staining (400×) (B). The lower panels showed enlarged views of the boxed areas in the upper panels in Figure A. The rightmost panels showed that enlarged views of the boxed areas in the left panels in Figure B. (C) Fluorescent intensity from 5 randomly selected microscopic fields per group in Figure B was captured and analyzed. (D) Representative Western blot analyses of cleaved-caspase3 protein expression. (E) Densitometric analysis of cleaved-caspase3 protein expression in Figure D. (F) Representative cytograms of apoptosis. (G) Quantification of cell apoptosis. All the statistical data are shown as the mean ±SEM, n=3. * p<0.05 vs. control group. † p<0.05 vs. PA group. ‡ p<0.05 vs. PA+BBR group.
dysfunction and apoptosis. In the present study we investigated the protein expression of CPT1A, PPARα, and PGC1α in TECs after PA treatment. However, the expression of key factors regulating FAO did not correspondingly increase, while FFA supply increased remarkably, suggesting that PA induces defective FAO in TECs, which might be responsible for intracellular lipid accumulation and apoptosis. D’Agati et al. found that renal triglyceride accumulation can be caused by defective FAO, which is mediated by PPARα and its target enzymes, including CPT1 [28]. However, the exact mechanism by which high lipid levels induce defective FAO in TECs is still uncertain and is the subject of ongoing investigations.

BBR has recently been demonstrated to have great effects on correcting lipid metabolism disorders [12,13]. In vivo and in vitro experiments suggest BBR can ameliorate PA-induced fat deposition in hepatocytes, and suppress inflammation, oxidative stress, and triglyceride accumulation in the liver of HFD-fed mice, thus inhibiting the progression of hepatic steatosis to steatohepatitis [30–33]. Moreover, it has been shown that BBR protects HFD-induced kidney damage in a mouse model [34], but the underlying mechanism has not been well defined. Our study shows that BBR can effectively protect TECs against PA-induced intracellular lipid accumulation and apoptosis, indicating that BBR protects the kidneys from lipid nephrotoxicity by reducing intracellular lipid accumulation. We further found that BBR greatly elevated CPT1A, PPARα, and PGC1α expressions in TECs. In HFD-fed fish, it is reported that BBR also increased hepatic CPT1A and PPARα mRNA expression, and decreased fat accumulation, alleviating oxidative stress and apoptosis in the liver [35]. We speculated that increasing FAO might be the mechanism underlying the protective effect of BBR against PA-induced intracellular lipid accumulation and apoptosis. As CPT1A is the rate-limiting enzyme for FAO, we further inhibited FAO with the CPT1A inhibitor Etomoxir in the present study, and found that Etomoxir counteracted the protective effect of BBR in TECs. All these results demonstrate that BBR can prevent intracellular lipid accumulation and therefore reduce apoptosis in PA-treated TECs by promoting FAO. In addition, some studies have found that BBR can activate AMP-activated protein kinase (AMPK) in fat and liver cells [14,36]. Moreover, previous studies have demonstrated that activating AMPK inhibits the activity of acetyl CoA carboxylase, and thus reduces malonyl CoA levels, resulting in increased CPT1 expression [37]. However, it remains unclear whether BBR promotes FAO by activating AMPK, which requires further studies in the future.

Conclusions

We have shown that PA can induce intracellular lipid accumulation and apoptosis in TECs, and defective FAO might be the mechanism. In addition, to the best of our knowledge, we provide the first evidence to suggest a new mechanism of BBR action in TECs that involves, sequentially, promoting FAO, lowering PA-induced excess intracellular lipid accumulation, and attenuating apoptosis. However, this was an in vitro study, and further in vivo studies are needed to confirm these results.

Acknowledgements

We are grateful for support from the Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases, where our work was done.

Conflicts of interest

None.

References:

1. Keane WF, Tommassini JE, Neff DR: Lipid abnormalities in patients with chronic kidney disease: Implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb, 2013; 20; 123–33
2. Pandya V, Rao A, Chaudhary K: Lipid abnormalities in kidney disease and management strategies. World J Nephrol, 2015; 4; 83–91
3. Samouilidou EC, Karpouza AP, Kostopoulos V et al: Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail, 2012; 34; 160–64
4. Moorhead JF, Chan MK, El-Nahas M, Varghese Z: Lipid nephrotoxicity in patients with chronic kidney disease. Kidney Int, 2006; 70: 1560–66
5. Weinberg M: Lipotoxicity. Kidney Int, 2008; 73; 1309–11
6. Weimberg (M): Lipotoxicity. Kidney Int, 2006; 70: 1560–66
7. Kang HM, Ahn SH, Choi P et al: Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med, 2015; 21; 37–46
8. Goldberg II, Trent CM, Schulze PC: Lipid metabolism and toxicity in the heart. Cell Metab, 2012; 15; 805–12
9. Lau CW, Yao XQ, Chen ZY et al: Cardiovascular actions of berberine. Cardiovasc Drug Rev, 2001; 19; 234–44
10. Taylor CE, Greenough WB 3rd: Control of diarrheal diseases. Annu Rev Public Health, 1989; 10; 221–44
11. Lan J, Zhao Y, Dong F et al: Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia and hypertension. J Ethnopharmacol, 2015; 161; 69–81
12. Kong W, Wei J, Abidi P et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 2004; 10; 1344–51
13. Wang Y, Tong Q, Shou JW et al: Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine. Theranostics, 2017; 7; 2443–51
14. Ni WJ, Ding HH, Tang LQ: Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. Eur J Pharmacol, 2015; 760; 103–12
15. Xue M, Zhang L, Yang MX et al: Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice. Int J Nanomedicine, 2015; 10; 5049–57
16. Gao N, Zhao TY, Li XI: The protective effect of berberine on beta-cell lipotoxicity. J Endocrinol Invest, 2011; 34; 124–30
17. Pascual G, Avgustinova A, Mejetta S et al: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature, 2017; 541: 41–45
18. Ruan XZ, Varghese Z, Moorhead JF: An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol, 2009; 5: 713–21
19. Zhou C, Moore L, Yool A et al: Renal tubular epithelial vacuoles – a marker for both hyperlipidaemia and ketoacidosis at autopsy. J Forensic Sci, 2015; 60: 638–41
20. Li LO, Klett EL, Coleman RA: Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta, 2010; 1801: 246–51
21. Green DR, Llambi F: Cell death signaling. Cold Spring Harb Perspect Biol, 2015; 7(12): pii: a006080
22. Elmore S: Apoptosis. A review of programmed cell death. Toxicol Pathol, 2007; 35: 495–516
23. Schelling JR: Tubular atrophy in the pathogenesis of chronic kidney disease progression. Pediatr Nephrol, 2016; 31: 693–706
24. Casals N, Zammit V, Herrero L et al: Carnitine palmitoyltransferase 1C: From cognition to cancer. Prog Lipid Res, 2016; 61: 134–48
25. McGarry JD, Brown NF: The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem, 1997; 244: 1–14
26. Lundsgaard AM, Fritzen AM, Kiens B: Molecular regulation of fatty acid oxidation in skeletal muscle during aerobic exercise. Trends Endocrinol Metab, 2018; 29: 18–30
27. Vega RB, Huss JM, Kelly DP: The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol, 2000; 20: 1868–76
28. D’Agati VD, Chagnac A, de Vries AP et al: Obesity-related glomerulopathy: Clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol, 2016; 12: 453–71
29. Zhang P, Ma D, Wang Y et al: Berberine protects liver from ethanol-induced oxidative stress and steatosis in mice. Food Chem Toxicol, 2014; 74: 225–32
30. Guo T, Woo SL, Guo X et al: Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. Sci Rep, 2016; 6: 22612
31. Sun Y, Yuan X, Zhang F et al: Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Sci Rep, 2017; 7: 11340
32. Zhao L, Cang Z, Sun H et al: Berberine improves gluconeogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord, 2017; 17: 13
33. Zhang Z, Li B, Meng X et al: Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci Rep, 2016; 6: 20848
34. Wu U, Cha Y, Huang X et al: Protective effects of berberine on high fat-induced kidney damage by increasing serum adiponectin and promoting insulin sensitivity. Int J Clin Exp Pathol, 2015, 8: 14486–92
35. Lu KL, Zhang DD, Wang LN et al: Molecular characterization of carnitine palmitoyltransferase IA in Megalobrama amblycephala and effects on its expression of feeding status and dietary lipid and berberine. Comp Biochem Physiol B Biochem Mol Biol, 2016; 191: 20–25
36. Li Y, Zhao X, Feng X et al: Berberine alleviates olanzapine-induced adipogenesis via the AMPKalpha-SREBP pathway in 3T3-L1 cells. Int J Mol Sci, 2016; 17: 1865
37. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 2005; 1: 15–25